Free Trial
→ Today's free pick (on me) (From Behind the Markets) (Ad)tc pixel
NYSEAMERICAN:OGEN

Oragenics Q3 2026 Earnings Results & Report

Oragenics logo
$0.19 -0.16 (-45.44%)
As of 12:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Oragenics reported Q3 2026 earnings on November 12, 2026. The company reported EPS of -$0.58.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes

Oragenics EPS Results

Actual EPS
-$0.58
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Oragenics Q3 2026 Earnings FAQ

Oragenics (NYSEAMERICAN:OGEN) reported earnings of -$0.58 per share for Q3 2026. The report was announced on Thursday, November 12, 2026.

Oragenics Earnings Headlines

Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028
November 12 at 4:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/12/3402141/0/en/oragenics-receives-nyse-american-approval-of-compliance-plan-and-extension-through-february-2028.html
Oragenics (NYSEAMERICAN:OGEN) Shares Climb 0.1% - Time to Buy?
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183560
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
November 13 at 1:00 AM  |  Weiss Ratings (Ad)
Oragenics Inc
October 22, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/ogen-oragenics-inc/vitals
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363159/0/en/oragenics-chief-medical-officer-to-present-at-ipac-rs-2026-nasal-innovation-forum.html
Oragenics, Inc.: Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
August 30, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69442136-oragenics-inc-oragenics-reports-continued-clinical-progress-provides-regulatory-and-nyse-american-listing-update-399.htm
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSEAMERICAN:OGEN) is a biotechnology company focused on developing intranasal medicines for neurological disorders. Its approach is designed to deliver drug candidates through the nasal passage directly to the brain, with the goal of addressing conditions for which conventional drug-delivery methods may be limited.

The company’s lead product candidate is ONP-002, an intranasal therapy being developed for the treatment of concussion and traumatic brain injury. Oragenics has also pursued additional preclinical programs targeting neurological and neurodegenerative diseases, although the development status and scope of these programs may change as the company advances its pipeline.

Founded in 1996 and headquartered in Florida, Oragenics historically worked on oral-care and antibiotic technologies, including products based on lantibiotics and beneficial bacteria. The company subsequently shifted its primary focus toward intranasal therapeutics for central nervous system disorders and has conducted its development activities principally in the United States.

View Oragenics Profile
Earnings Tools